To further investigate the therapeutic potential of these findings, we tested the impact of pharmacological inhibition of MCL-1 in established mammary tumours in vivo and found that MCL-1 inhibition or knock-down inhibited TN breast cancer growth in xenograft experiments (Fig. 4).